Page 1

PRESS RELEASE BIOMÉRIEUX bioMérieux - Third - Quarter 2021 Business Review Organic growth of 12.1 % at constant exchange rates and scope of consolidation over the first nine months of the year : • € 2,452 million in sales Up 8.2 % as reported Q3 sales organic growth at 11.6 % , significantly above expectations due to a strong upturn in US respiratory panels demand , combined with a solid momentum in all other applications Upward revision of 2021 outlook : In the light of Q3 higher - than - expected respiratory multiplexing testing demand , bioMérieux is raising its FY'21 outlook . Full year sales are now expected to grow between 4 % and 7 % ( previously : at neutral to mid - single digit rate ) , at constant exchange rates and scope of consolidation . Contributive operating income before non- recurring items should be above € 700 million ( previously : in line with 2020 ) at current exchange rates . Alexandre Mérieux , Chairman and Chief Executive Officer , said : “ During the third quarter of 2021 , we saw an uptake of multiplexing respiratory demand in the US , while all other business lines , namely microbiology , immunoassays and industrial applications , kept on maintaining solid growth . We are therefore raising upward 2021 sales revenue and contributive operating income outlook . This extraordinary 2021 operating income is however embedding a low level of operating expenses within the pandemic context , and is therefore not projectable as such beyond 2021. ” Marcy l'Étoile , October 21 , 2021 - bioMérieux , a world leader in the field of in vitro diagnostics , today releases its business review for the nine months ended September 30 , 2021 . SALES Consolidated sales reach € 2,452 million for the first nine months of 2021 versus € 2,266 million for the prior- year period , representing growth of 8.2 % as reported . Organic growth ( at constant exchange rates and scope of consolidation ) reaches 12.1 % for the first nine months of the year fueled by a stronger - than - expected third quarter . Exchange rate movements result in a negative currency effect of € 87.3 million , primarily due to the decline in the US dollar and to a lesser extend certain Latin American and ASPAC currencies against the euro during the period . Analysis of sales In € millions SALES - NINE MONTHS ENDED SEPTEMBER 30 , 2020 2,266 Currency effect -87 -3.9 % Changes in scope of consolidation Organic growth ( at constant exchange rates and scope of consolidation ) +273 + 12.1 % SALES - NINE MONTHS ENDED SEPTEMBER 30 , 2021 2,452 + 8.2 % Note : Unless otherwise stated , growth is expressed year - on - year at constant exchange rates and scope of consolidation ( like - for - like ) .